Sphera Funds Management’s Intellia Therapeutics NTLA Stock Holding History

Sphera Funds Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-128,780	Closed	-$1.21M	–	128
2025 Q2	$1.21M	Sell	128,780 -252,300	-66%	-$2.07M	0.28%	80
2025 Q1	$2.71M	Sell	381,080 -85,000	-18%	-$859K	0.62%	50
2024 Q4	$5.43M	Buy	466,080 +175,000	+60%	+$2.73M	0.98%	37
2024 Q3	$5.98M	Buy	291,080 +151,661	+109%	+$3.5M	0.95%	38
2024 Q2	$3.12M	Buy	+139,419	New	+$3.32M	0.43%	66
2021 Q4	–	Sell	-23,647	Closed	-$3.17M	–	117
2021 Q3	$3.17M	Sell	23,647 -28,903	-55%	-$4.38M	0.27%	82
2021 Q2	$8.51M	Buy	+52,550	New	+$4.09M	0.58%	47
2018 Q2	–	Sell	-160,000	Closed	-$3.37M	–	117
2018 Q1	$3.37M	Buy	+160,000	New	+$3.93M	0.51%	56

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CGH

Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sphera Funds Management's NTLA Position: Q3 2025 in Review

Sphera Funds Management sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 128,780 shares — an estimated $1.21M sold.

Sphera Funds Management first reported a position in NTLA in Q1 2018 and held it in 8 quarters. The position peaked at $8.51M in Q2 2021. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

Sphera Funds Management reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
Sphera Funds Management sold 128,780 Intellia Therapeutics shares in Q3 2025, an estimated $1.21M.
Sphera Funds Management first reported a position in Intellia Therapeutics in Q1 2018 and held it in 8 quarters.
Sphera Funds Management's Intellia Therapeutics position peaked at $8.51M in Q2 2021.
282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Sphera Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.